Loading
DermaSensor makes a handheld device that shines light into a worrying skin spot and uses a trained algorithm to say whether it should be looked at more closely for skin cancer. It is meant for family doctors rather than skin specialists.
DermaSensor Inc., of Miami, Florida, was founded in 2009, according to the company, by Maurice Ferre and Christopher Dewey, using elastic scattering spectroscopy invented by Irving Bigio of Boston University. Its wireless handheld device measures light reflectance from a skin lesion and an algorithm compares the signature with lesions of known pathology to assess the risk of the three common skin cancers. The company reports FDA De Novo clearance in early 2024 with US launch in mid-2024, a CE mark under the MDD and later a Class IIb CE mark under the MDR announced in June 2026 with an NHS collaboration, and a German launch in September 2026. A post-market surveillance study (NCT06666790) evaluates the sensitivity of the device and investigators on lesions concerning for melanoma. In October 2025 it raised 16 million US dollars in Series B funding, which it said brought total investment to 43 million US dollars, and in September 2026 it announced a further 5 million US dollars with a public round on Wefunder. Its first registered cancer study, NCT06666790, was posted on ClinicalTrials.gov in October 2024.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Series B · Existing investors with Pier 70 Ventures, Kern Venture Group, GenHenn Capital and an undisclosed strategic investor; the company states total investment of 43 million US dollars | 2025 | $16M | dermasensor.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Shares Cutaneous squamous cell carcinoma, Basal cell carcinoma, Skin cancer (all types), Melanoma.
Shares Cutaneous squamous cell carcinoma, Basal cell carcinoma, Skin cancer (all types).
Shares Cutaneous squamous cell carcinoma, Basal cell carcinoma, Skin cancer (all types).
Shares Skin cancer screening (visual skin examination), Skin cancer (all types), Melanoma.
Shares Skin cancer screening (visual skin examination), Skin cancer (all types), Melanoma.
Shares Basal cell carcinoma, Skin cancer (all types), Melanoma.
Shares Basal cell carcinoma, Skin cancer (all types), Melanoma.
Shares Basal cell carcinoma, Skin cancer (all types), Melanoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/